Earthworm extract could tame diabetes inflammation

NCT ID NCT07684625

Completed Disease control Sponsor: Universitas Sebelas Maret Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether an extract from the earthworm Lumbricus rubellus (DLBS1033) can reduce inflammation and improve quality of life in people with type 2 diabetes. Sixty adults on standard diabetes therapy will receive either a low or high dose of the extract or continue standard care alone for four weeks. Researchers will measure changes in blood markers of inflammation (hs-CRP) and blood vessel health (VEGF), along with self-reported well-being.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lumbricus rubellus (earthworm) extract DLBS1033
What this could lead to: If it works, this could point toward a natural supplement to help control inflammation and blood vessel health in type 2 diabetes.
What could go wrong: This is a small, short-term trial (60 people, 4 weeks). The extract may not reduce inflammation or improve quality of life more than standard diabetes care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Dr. Moewardi Regional General Hospital

Surakarta, Central Java, 57126, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.